Fewer than one in 10 patients that would benefit from GLP-1 drugs like Wegovy are able to get them, states the World Health Organization as it releases its initial guidance on the therapies.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just access to these injectable treatments.
Based on forecasts, over two billion will be obese by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be managed with comprehensive and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant obstacles to broad access to the treatments that can assist patients in reducing substantial weight, says the organization.
Skinny Jab Scarcity
Even in the current most favorable case, the supply of GLP-1 therapies might only reach around 100 million people – less than 10% of eligible patients, per the health organization.
The recommendation calls on governments and firms to expand availability, via strategies including voluntary licensing.
A patent on the active ingredient – the primary component of a leading brand – is due to expire in several nations in 2026.
The Way Weight-Loss Injections Function
These medications replicate a natural hormone to reduce digestion speed, curb appetite and boost the sense of being full so people reduce food intake.
People commonly start to lose weight after several weeks of starting on the once-weekly jabs.
Research indicates users may regain a significant portion a year later of stopping the drug, when their typical appetite return.
To be above a healthy weight increases your likelihood for experiencing diseases, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns people in countries worldwide and was linked to millions of deaths worldwide in 2024, as per the health agency.
